Lv4
478 积分 2024-05-30 加入
How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC
14天前
已完结
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
1个月前
已完结
Claudin 18.2 as a novel therapeutic target
2个月前
已完结
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
2个月前
已完结
Co-occurring EGFR p.E709X mutation Mediates Primary Resistance to the Third-generation EGFR-TKIs in EGFR p.G719X-mutant Patients with Advanced NSCLC
3个月前
已完结
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results
5个月前
已完结
Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer
5个月前
已完结
Comprehensive review of ROS1 tyrosine kinase inhibitors (TKIs)-classified by structural designs and mutation spectrum [solvent front mutation (G2032R) and central β-sheet 6 (Cβ6) mutation (L2086F)]
5个月前
已完结
Detection of multiple types of cancer driver mutations using targeted RNA sequencing in non–small cell lung cancer
5个月前
已完结
Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC
5个月前
已完结
皖公网安备34019202002308
